Name: Latest research reports of Eris Lifesciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Eris Lifesciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Eris Lifesciences Ltd.

NSE: ERIS | BSE: 540596 | ISIN: INE406M01024 | Industry: Pharmaceuticals
| Mid-range Performer

1675.9000 -23.30 (-1.37%)

NSE Sep 12, 2025 15:31 PM

52.74% Gain from 52W Low

Volume: 711.9K

High volume today

Eris Lifesciences Ltd.

14 Dec 2020, 12:00AM

1675.90

-1.37%

[Initiation] Eris Lifesciences (BUY): Chronic franchise, FCF growth underappreciated; initiate with BUY

Buy: Eris Lifesciences Ltd.

BOB Capital Markets Ltd.

Eris Lifesciences' (ERIS) earnings are at inflection point and we expect a 16% EBITDA CAGR over FY21-FY24 (vs. 8%, FY18-FY21).

Eris Lifesciences Ltd. has an average target of 1581.00 from 3 brokers.